GSK and Sanofi join forces to work on coronavirus vaccine

GSK is already offering access to its technology to smaller teams, such as a vaccine effort at the University of Queensland, but this is the first collaboration that would have the ability to rapidly scale up manufacturing.

本周二(4月14日)，沃姆斯利表示，葛兰素史克不会在新冠疫情期间从疫苗中获利，所有收入都将用于扩大生产规模和疫情应对相关研究。

两家公司计划在今年下半年开始第一阶段临床试验，并表示，一旦试验取得成功，这种疫苗可能会在2021年下半年大量投放市场。

The vaccine is based on an existing DNA-based technology that Sanofi uses to make its flu vaccine.

Paul Hudson, the chief executive of Sanofi, said: “As the world faces this unprecedented global health crisis, it is clear that no one company can go it alone. That is why Sanofi is continuing to complement its expertise and resources with our peers, such as GSK, with the goal to create and supply sufficient quantities of vaccines that will help stop this virus.”

葛兰素史克将贡献一种被称为佐剂的附加物质。它可以与疫苗混合，引发更加强烈的免疫反应。这种技术也曾应用于甲型H1N1流感的疫苗研发。

葛兰素史克已经在向规模较小的团队提供技术，比如澳大利亚昆士兰大学的疫苗项目，但与赛诺菲的合作是首次能够快速提升生产规模的合作。

赛诺菲合成出了一种对这种蛋白的基因序列进行编码的DNA片段。当这段DNA被植入实验室里的一种无害细菌时，它会产生大量微小的抗原副本，而不是活性新冠病毒本身。赛诺菲希望它们能够在不引发疾病的情况下触发抗体反应。

英国葛兰素史克公司和法国赛诺菲集团正在合作研发一种高科技疫苗，这两家公司加起来拥有世界上最大规模疫苗生产能力。两家公司称，这种疫苗可能在数月后开始进行人体试验。

这一合作意义重大，因为一旦成功，两家公司有能力生产出全世界可能需要的数亿剂疫苗。

Emma Walmsley, the chief executive of GSK, described the collaboration as “unprecedented”.

She said: “What is not common is you’ve got two of the biggest vaccine manufacturers in the world coming together. Both bring significant manufacturing capacity. We believe we’ll be able to make hundreds of millions of doses by the end of next year.”

她说：“世界上最大的两家疫苗生产商走到一起，这并不常见。二者都会带来巨大的生产能力。我们相信，到明年年底，我们将能够生产出数亿剂(疫苗)。”

全球最大的两家疫苗公司英国葛兰素史克公司和法国赛诺菲集团正合作研发新冠肺炎疫苗，或将在数月后开始人体试验。如果试验获得成功，疫苗将在2021年下半年大量投放市场。

葛兰素史克首席执行官埃玛·沃姆斯利称，这一合作“前所未有”。

A worker checks the temperature of a customer at the entrance of a supermarket in Turin, Italy, on Tuesday, as the spread of the novel coronavirus continues. [MASSIMO PINCA/REUTERS]Two of the world’s biggest vaccine companies have joined forces in an “unprecedented” collaboration to develop a Covid-19 vaccine.

GSK and Sanofi join forces to work on coronavirus vaccine

[责编:周杨]

The companies plan to start phase one trials in the second half of this year and, if successful, say the vaccine could be widely available by the second half of 2021.

赛诺菲首席执行官保罗·赫德森说：“在世界面临这一前所未有的全球性卫生危机之际，显然没有任何一家企业能够单打独斗。正因为如此，赛诺菲将继续与葛兰素史克等同行企业互相补充专业技能和资源，目标是生产和供应足够数量的疫苗，从而帮助遏制新冠病毒。”

英法制药巨头联手研发新冠疫苗 明年或大量上市